EP1301476A1 - New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation - Google Patents

New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Info

Publication number
EP1301476A1
EP1301476A1 EP01961472A EP01961472A EP1301476A1 EP 1301476 A1 EP1301476 A1 EP 1301476A1 EP 01961472 A EP01961472 A EP 01961472A EP 01961472 A EP01961472 A EP 01961472A EP 1301476 A1 EP1301476 A1 EP 1301476A1
Authority
EP
European Patent Office
Prior art keywords
receptor
antagonist
htg
agonist
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01961472A
Other languages
German (de)
English (en)
French (fr)
Inventor
Sukhwinder Jossan
Björn M. NILSSON
Kjell S. Sakariassen
Jan Svartengren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BenevolentAI Cambridge Ltd
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of EP1301476A1 publication Critical patent/EP1301476A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP01961472A 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation Withdrawn EP1301476A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0002754 2000-07-21
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Publications (1)

Publication Number Publication Date
EP1301476A1 true EP1301476A1 (en) 2003-04-16

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01961472A Withdrawn EP1301476A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Country Status (19)

Country Link
EP (1) EP1301476A1 (sh)
JP (1) JP2004504376A (sh)
KR (1) KR100845450B1 (sh)
CN (1) CN1221254C (sh)
AU (2) AU2001282734B2 (sh)
BR (1) BR0112661A (sh)
CA (1) CA2411192A1 (sh)
EA (1) EA006604B1 (sh)
HK (1) HK1057536A1 (sh)
HU (1) HUP0301346A3 (sh)
IL (1) IL154057A0 (sh)
MX (1) MXPA03000548A (sh)
NO (1) NO20030304L (sh)
NZ (1) NZ523216A (sh)
PL (1) PL360309A1 (sh)
SE (1) SE0002754D0 (sh)
WO (1) WO2002008178A1 (sh)
YU (1) YU2603A (sh)
ZA (1) ZA200210234B (sh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006205B1 (ru) * 2000-11-02 2005-10-27 Уайт 1-арил- или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
BR0210411A (pt) * 2001-06-15 2004-08-17 Hoffmann La Roche Derivados 4-piperazinilindol com afinidade para o receptor 5-ht6
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
PL209872B1 (pl) 2002-03-27 2011-10-31 Glaxo Group Ltd Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
ES2358288T3 (es) * 2007-08-01 2011-05-09 Laboratorios Del Dr. Esteve S.A. Combinación de al menos dos ligandos de 5ht6.
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
CN102458579B (zh) 2009-06-15 2014-11-05 武田药品工业株式会社 吡嗪并氧氮杂*衍生物
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0208178A1 *

Also Published As

Publication number Publication date
NO20030304D0 (no) 2003-01-20
CA2411192A1 (en) 2002-01-31
CN1443162A (zh) 2003-09-17
IL154057A0 (en) 2003-07-31
EA006604B1 (ru) 2006-02-24
NZ523216A (en) 2005-05-27
KR20030036599A (ko) 2003-05-09
MXPA03000548A (es) 2004-04-05
CN1221254C (zh) 2005-10-05
YU2603A (sh) 2006-05-25
ZA200210234B (en) 2004-03-18
WO2002008178A1 (en) 2002-01-31
AU2001282734B2 (en) 2006-10-12
EA200300183A1 (ru) 2003-08-28
JP2004504376A (ja) 2004-02-12
AU8273401A (en) 2002-02-05
PL360309A1 (en) 2004-09-06
NO20030304L (no) 2003-03-12
SE0002754D0 (sv) 2000-07-21
BR0112661A (pt) 2003-06-24
HUP0301346A2 (hu) 2003-08-28
KR100845450B1 (ko) 2008-07-10
HUP0301346A3 (en) 2005-05-30
HK1057536A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2001282734B2 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
AU2001282734A1 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
Davies et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology
US6489341B1 (en) Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6818639B2 (en) Pharmaceutical combination formulation and method of treatment with the combination
JP2011006431A (ja) アデノシンＡ２ａレセプターアンタゴニストの使用
JP2765845B2 (ja) 中止症候群の予防の治療薬
CN1335850A (zh) 化合物
CA2332814C (en) Combination therapy for treatment of refractory depression
ES2757922T3 (es) Agonistas y composiciones del receptor 5-HT2C y métodos de uso
JP2008517976A (ja) Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
JP2009504737A (ja) 脈管疾患の治療又は予防のためのｐａｒ−１／ｐａｒ−４阻害剤の使用
AU4008899A (en) Combination therapy for treatment of bipolar disorders
AU2004204827A1 (en) Method of treating nausea, vomiting, retching or any combination thereof
KR100397525B1 (ko) 뇌혈관 장해에 수반되는 정신증후치료제
JP4740152B2 (ja) 末梢性５−ｈｔ受容体の修飾因子
WO2007024600A2 (en) Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
WO2002036113A1 (en) Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
ES2360164A1 (es) Ligandos de 5ht6 en el aumento de peso inducido por fármacos.
SK9002001A3 (en) 5ht1 antagonists for antidepressant therapy
V Ivachtchenko et al. Small molecule 5-HT6R ligands: a comprehensive insight into their selectivity and activity
WO2001095902A1 (en) A composition comprising a combination of receptor agonists and antagonists
Steiner et al. D4/5-HT2A Receptor antagonists: LU-111995 and other potential new antipsychotics in development
WO2001095902A9 (en) A composition comprising a combination of receptor agonists and antagonists
JP2010506884A (ja) Ｎｋ−１受容体アンタゴニストおよびｓｓｒｉを含む、耳鳴、聴力障害または耳鳴と聴力障害の治療用組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20021204

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SVARTENGREN, JAN

Inventor name: SAKARIASSEN, KJELL, S.

Inventor name: NILSSON, BJOERN, M.

Inventor name: JOSSAN, SUKHWINDER

17Q First examination report despatched

Effective date: 20040223

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOVITRUM AB (PUBL)

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROXIMAGEN LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111011